Canadian Cancer Trials Group - Canadian Collaborating Clinical Trials Network

摘要 癌症生物学的变革性进展和从分子水平表征癌症的技术 水平，再加上新药和细胞疗法的迅速扩展，要求从根本上重新 评估临床试验设计和实施，以确保患者和社会利益最大化。这个 加拿大癌症试验集团(CCTG)与美国调查人员和组织在 NCTN，它强调国际合作，以进行最终的实践改变试验，试验 在罕见的癌症环境中，以及测试精确医学策略的试验中。作为加拿大的合作伙伴 NCTN的临床试验网络(CCCTN)，CCTG扩展了NCTN的科学专长：1) 让其网络中最优秀和最聪明的人担任NCTN的领导角色；2)增加临床试验 通过其国家网络(包括加拿大的所有中心)提高能力；以及，3)便利获得 加拿大患者，这对于在罕见人群中测试干预措施的试验尤为重要。CCTG 促进科学概念的发展、收益、生物量收集和网络领导，以及 在审判行为的工具组件方面具有专业知识(包括信息技术和 规则)。CCTG开发并参与NCTN成人癌症试验组合，涉及乳腺癌、肺癌、 泌尿系和胃肠道恶性肿瘤，在不常见/罕见的未满足需求的情况下，例如 血液癌、皮肤癌、脑癌、头颈癌，包括阿亚的青少年和年轻人 审判。此外，CCTG利用机会将其试验活动范围扩大到包括外科手术 以及生活方式干预和成像以及数字健康终端。研究纳入了翻译 科学和其他相关端点，以丰富从NCTN试验和方法以及 改进临床试验设计、终点和执行的技术开发。最后，CCTG 提供来自NCTN试验的试验数据集，作为其数据共享政策的一部分。作为CCCTN，CCTG， 加拿大最大和最有经验的临床试验部门，创造和提供创新的战略， 来自NCTN加速将科学进步转化为癌症改善 改善被诊断为癌症的儿童、青少年和成年人的生活的治疗。

Summary The transformational advances in cancer biology and technologies to characterize cancers at a molecular level, combined with the rapid expansion of novel drugs and cellular therapies, mandates a fundamental re- evaluation of clinical trial design and delivery to ensure maximal patient and societal benefits. The Canadian Cancer Trials Group (CCTG) has strong partnerships with US investigators and groups within the NCTN, which emphasize international collaboration to conduct definitive practice-changing trials, trials in rare cancers settings, and trials testing precision-medicine strategies. As the Canadian Collaborating Clinical Trials Network (CCCTN) of the NCTN, CCTG expands NCTN's scientific expertise by: 1) Involving the best and brightest within its network in NCTN leadership roles; 2) Increasing clinical trial capacity through its national network, which includes all centres in Canada; and, 3) Facilitates access to Canadian patients, which is particularly important for trials testing interventions in rare populations. CCTG contributes to scientific concept development, accrual, biospecimen collection, and network leadership, and has expertise in instrumental components of trial conduct (including information technology and regulations). CCTG develops and participates in NCTN adult cancer trial portfolios in breast, lung, urological, and gastrointestinal malignancies, in uncommon/rare settings of unmet need such as hematological, skin, brain and head and neck cancers, and includes adolescents and young adults on AYA trials. In addition, CCTG capitalizes on opportunities to extend its scope of trial activity to include surgical and lifestyle interventions and imaging and digital health endpoints. Research incorporates translational science and other correlative endpoints to enrich information derived from NCTN trials and methods and technology development to improve clinical trial designs, endpoints, and execution. Finally, CCTG contributes trial datasets from NCTN trials as part of its data sharing policy. As the CCCTN, CCTG, Canada's largest and most experienced clinical trials unit, creates and delivers innovative strategies that arise from the NCTN accelerating the translation of scientific advances into improvements in cancer treatments improving the lives of children, adolescents, and adults diagnosed with cancer.